The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells
Abstract
Abstract Multiple growth factors can stimulate quiescent vascular smooth muscle cells to exit from G0 and reenter the cell cycle. The macrolide antibiotic rapamycin, bound to its cytosolic receptor FKBP, is an immunosuppressant and a potent inhibitor of cellular proliferation. In the present study, the antiproliferative effects of rapamycin on human and rat vascular smooth muscle cells were examined and compared with the effects of a related immunosuppressant, FK520. In vascular smooth muscle cells, rapamycin, at concentrations as low as 1 ng/mL, inhibited DNA synthesis and cell growth. FK520, an analogue of the immunosuppressant FK506, is structurally related to rapamycin and binds to FKBP but did not inhibit vascular smooth muscle cell growth. Molar excesses of FK520 blocked the antiproliferative effects of rapamycin, indicating that the effects of rapamycin required binding to FKBP. Rapamycin-FKBP inhibited retinoblastoma protein phosphorylation at the G1/S transition. This inhibition of retinoblastoma protein phosphorylation was associated with a decrease in p33 cdk2 kinase activity. These observations suggest that rapamycin, but not FK520, inhibits vascular smooth muscle cell proliferation by reducing cell-cycle kinase activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle
Matsushime, H., Roussel, M. F., Ashmun, R. A., & Sherr, C. J. (1991) · Cell · doi:10.1016/0092-8674(91)90101-4 · Cited by 1,167
Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF
Ferns, G. A. A., Raines, E. W., Sprugel, K. H., Motani, A. S., Reidy, M. A., & Ross, R. (1991) · Science · doi:10.1126/science.1653454 · Cited by 1,065
Formation and Activation of a Cyclin E-cdk2 Complex During the G 1 Phase of the Human Cell Cycle
Koff, A., Giordano, A., Desai, D., Yamashita, K., Harper, J. W., Elledge, S., Nishimoto, T., Morgan, D. O., Franza, B. R., & Roberts, J. M. (1992) · Science · doi:10.1126/science.1388288 · Cited by 1,043
Regulation of retinoblastoma protein functions by ectopic expression of human cyclins
Hinds, P. W., Mittnacht, S., Dulic, V., Arnold, A., Reed, S. I., & Weinberg, R. A. (1992) · Cell · doi:10.1016/0092-8674(92)90249-c · Cited by 995
Physical interaction of the retinoblastoma protein with human D cyclins
Dowdy, S. F., Hinds, P. W., Louie, K., Reed, S. I., Arnold, A., & Weinberg, R. A. (1993) · Cell · doi:10.1016/0092-8674(93)90137-f · Cited by 744
Gu, W., Schneider, J. W., Condorelli, G., Kaushal, S., Mahdavi, V., & Nadal-Ginard, B. (1993) · Cell · doi:10.1016/0092-8674(93)90110-c · Cited by 729
Austin, G. E., Ratliff, N. B., Hollman, J., Tabei, S., & Phillips, D. F. (1985) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(85)80174-1 · Cited by 574
Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells.
Berk, B. C., Vekshtein, V, Gordon, H. M., & Tsuda, T. (1989) · Hypertension · doi:10.1161/01.hyp.13.4.305 · Cited by 556
Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins.
Hannon, G. J., Demetrick, D., & Beach, D. (1993) · Genes & Development · doi:10.1101/gad.7.12a.2378 · Cited by 465
Morishita, R., Gibbons, G. H., Ellison, K. E., Nakajima, M., Zhang, L., Kaneda, Y., Ogihara, T., & Dzau, V. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8474 · Cited by 458
Cited by
Pathology of Drug-Eluting Stents in Humans
Joner, M., Finn, A. V., Farb, A., Mont, E. K., Kolodgie, F. D., Ladich, E., Kutys, R., Skorija, K., Gold, H. K., & Virmani, R. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.042 · Cited by 2,744
Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications
Lüscher, T. F., Steffel, J., Eberli, F. R., Joner, M., Nakazawa, G., Tanner, F. C., & Virmani, R. (2007) · Circulation · doi:10.1161/circulationaha.106.675934 · Cited by 906
Groth, C. G., Bäckman, L., Morales, J.-M., Calne, R., Kreis, H., Lang, P., Touraine, J.-L., Claesson, K., Campistol, J. M., Durand, D., et al. (1999) · Transplantation · doi:10.1097/00007890-199904150-00017 · Cited by 878
Coronary stents: A materials perspective
Mani, G., Feldman, M. D., Patel, D., & Agrawal, C. M. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.11.042 · Cited by 866
Sousa, J. E., Costa, M. A., Abizaid, A., Abizaid, A. S., Feres, F., Pinto, I. M. F., Seixas, A. C., Staico, R., Mattos, L. A., Sousa, A. G. M. R., et al. (2001) · Circulation · doi:10.1161/01.cir.103.2.192 · Cited by 793
Sirolimus: its discovery, biological properties, and mechanism of action
Sehgal, S. N. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00211-2 · Cited by 779
Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model
Suzuki, T., Kopia, G., Hayashi, S.-I., Bailey, L. R., Llanos, G., Wilensky, R., Klugherz, B. D., Papandreou, G., Narayan, P., Leon, M. B., et al. (2001) · Circulation · doi:10.1161/hc3601.093987 · Cited by 708
Sousa, J. E., Costa, M. A., Abizaid, A. C., Rensing, B. J., Abizaid, A. S., Tanajura, L. F., Kozuma, K., Van Langenhove, G., Sousa, A. G. M. R., Falotico, R., et al. (2001) · Circulation · doi:10.1161/hc4201.098056 · Cited by 672
Sehgal, S. N. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00045-9 · Cited by 663
Cardiac Allograft Vasculopathy: Recent Developments
Schmauss, D., & Weis, M. (2008) · Circulation · doi:10.1161/circulationaha.107.711911 · Cited by 587
Rapamycin inhibits vascular smooth muscle cell migration.
Poon, M., Marx, S. O., Gallo, R., Badimon, J. J., Taubman, M. B., & Marks, A. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119038 · Cited by 511
Self-citationMolecular Basis of Restenosis and Drug-Eluting Stents
Costa, M. A., & Simon, D. I. (2005) · Circulation · doi:10.1161/01.cir.0000163587.36485.a7 · Cited by 510
Gallo, R., Padurean, A., Jayaraman, T., Marx, S., Roque, M., Adelman, S., Chesebro, J., Fallon, J., Fuster, V., Marks, A., et al. (1999) · Circulation · doi:10.1161/01.cir.99.16.2164 · Cited by 490
Self-citationRapamycin in transplantation: A review of the evidence
Saunders, R. N., Metcalfe, M. S., & Nicholson, M. L. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00460.x · Cited by 461
Bench to Bedside: The Development of Rapamycin and Its Application to Stent Restenosis
Marx, S. O., & Marks, A. R. (2001) · Circulation · doi:10.1161/01.cir.104.8.852 · Cited by 447
Self-citationDuda, S. H., Pusich, B., Richter, G., Landwehr, P., Oliva, V. L., Tielbeek, A., Wiesinger, B., Hak, J. B., Tielemans, H., Ziemer, G., et al. (2002) · Circulation · doi:10.1161/01.cir.0000029746.10018.36 · Cited by 446
Use of Rapamycin Slows Progression of Cardiac Transplantation Vasculopathy
Mancini, D., Pinney, S., Burkhoff, D., LaManca, J., Itescu, S., Burke, E., Edwards, N., Oz, M., & Marks, A. R. (2003) · Circulation · doi:10.1161/01.cir.0000070421.38604.2b · Cited by 442
Self-citationCardiac Allograft Vasculopathy: A Review
Weis, M., & von Scheidt, W. (1997) · Circulation · doi:10.1161/01.cir.96.6.2069 · Cited by 433
Regulation of vascular smooth muscle cell differentiation
Rzucidlo, E. M., Martin, K. A., & Powell, R. J. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.03.001 · Cited by 414
Smooth muscle cell-driven vascular diseases and molecular mechanisms of VSMC plasticity
Frismantiene, A., Philippova, M., Erne, P., & Resink, T. J. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.08.019 · Cited by 406
National Cancer Institute (2020) · Definitions · doi:10.32388/f3vp5p · Cited by 383
Vascular Smooth Muscle Cell Proliferation in Restenosis
Marx, S. O., Totary-Jain, H., & Marks, A. R. (2011) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.110.957332 · Cited by 354
Self-citationNew Frontiers in Cardiology: Drug-Eluting Stents: Part I
Sousa, J. E., Serruys, P. W., & Costa, M. A. (2003) · Circulation · doi:10.1161/01.cir.0000069330.41022.90 · Cited by 349
Oshiro, N., Takahashi, R., Yoshino, K.-I., Tanimura, K., Nakashima, A., Eguchi, S., Miyamoto, T., Hara, K., Takehana, K., Avruch, J., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702636200 · Cited by 318
De Meyer, G. R. Y., Grootaert, M. O. J., Michiels, C. F., Kurdi, A., Schrijvers, D. M., & Martinet, W. (2015) · Circulation Research · doi:10.1161/circresaha.116.303804 · Cited by 287
Curcumin inhibits the mammalian target of rapamycin‐mediated signaling pathways in cancer cells
Beevers, C. S., Li, F., Liu, L., & Huang, S. (2006) · International Journal of Cancer · doi:10.1002/ijc.21932 · Cited by 256
Metadata
- Authors
- Marx, S. O., Jayaraman, T., Go, L. O., & Marks, A. R.
- Venue
- Circulation Research
- Published
- 1995-03
- Volume
- 76
- Issue
- 3
- Pages
- 412-417
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2067196635
- Cited by
- 599
- References
- 26
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.